Cytokinetics

CYTOKINETICS INC

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

CYTK

Biotech

Large Cap

News

Health Care

Movers

Trading Ideas

General

FDA extended the aficamten decision deadline to Dec. 26 after classifying the REMS submission as a major amendment to the NDA review.

FDA Pushes Potential Approval For Cytokinetics&#39; Experimental Heart Drug By Three Months

Kazan,,Russia,-,Dec,02,,2021:,Square,,Inc.,Changes,Name

Pre-Market Outlook

Markets

AAPL

AMZN

ARDX

ROKU

TEAM

TREE

Block, Atlassian, Apple, Roku, Amazon And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Analyst,Works,On,Personal,Computer,Showing,Business,Analytics,Dashboard,With

Initiation

Analyst Ratings

ACCS

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

Cytokinetics, Incorporated - Common Stock

Cytokinetics Inc

Press Releases

Cytokinetics, Incorporated (CYTK) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

Securities Fraud Investigation Into Cytokinetics, Incorporated (CYTK) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

Cytokinetics to Host Symposium on Contemporary Landscapes in Muscle Biology

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

Cytokinetics to Participate in the Jefferies Global Healthcare Conference

Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Arcellx

ADMA Biologics

Akero Therapeutics

Alkermes

CRISPR Therapeutics

Krystal Biotech

Kymera Therapeutics

Merus

Metsera

Nuvalent

Vaxcyte

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Rhythm Pharmaceuticals

Soleno Therapeutics

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

TG Therapeutics

Telix Pharmaceuticals Limited - American Depositary Shares

Telix Pharmaceuticals

Viking Therapeutics

Zai Lab Limited - American Depositary Shares

Zai Lab

JP Morgan

Mizuho

Needham

Barclays

RBC Capital

Comments

Cytokinetics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell